Biesterfeld S, Schuh S, Muys L, Rath W, Mittermayer C, Schröder W
Institute of Pathology, University of Aachen, D-52057 Aachen, Germany.
Oncol Rep. 1999 Jan-Feb;6(1):205-9. doi: 10.3892/or.6.1.205.
The expression of growth factors is considered as an important diagnostic and prognostic feature in tumor pathology. We investigated the value of the immunohistochemical EGF-receptor expression (EGF-R) in 30 squamous cell carcinomas of the uterine cervix, treated by radical hysterectomy and lymphadenectomy according to the Wertheim-Meigs-Okabayashi technique. Immunohistochemical reactions were performed on 4 microm sections from paraffin-embedded tissue, using an indirect peroxidase method. The staining results were evaluated semiquantitatively as negative (n=9; 30%) or as slightly, moderately or severely positive (n=21; 70%). The EGF-R-negative tumors were found in less advanced tumor stages. None had invaded into the parametrium (100%), eight were staged as T1 (89%), seven as N0 (78%), and seven showed no evidence for lymphangiosis carcinomatosa (78%). The respective values for the EGF-R-positive tumors ranged from 52% to 67%. However, only the difference in parametral invasion (EGF-R-negative: 0%, EGF-R-positive: 38%) was statistically significant (p=0.0306), probably due to the small number of cases. The EGF-R-expression was not correlated to histomorphological tumor grading. The results of this study indicate an inverse correlation between EGF-R expression and tumor spread. Assuming that this trend could be confirmed by a larger group of patients, immunostaining for EGF-R in a tumor biopsy could be useful to adapt surgical strategies and adjuvant therapy in the individual patient. Moreover, the EGF-R is an interesting target for immunotherapeutic approaches in squamous cell cervical carcinoma.
生长因子的表达被认为是肿瘤病理学中一项重要的诊断和预后特征。我们研究了免疫组化检测表皮生长因子受体表达(EGF-R)在30例子宫颈鳞状细胞癌中的价值,这些病例均按照Wertheim-Meigs-Okabayashi技术行根治性子宫切除术及淋巴结清扫术。采用间接过氧化物酶法,对石蜡包埋组织的4微米切片进行免疫组化反应。染色结果进行半定量评估,分为阴性(n = 9;30%)或轻度、中度、重度阳性(n = 21;70%)。EGF-R阴性肿瘤多处于较早期肿瘤阶段。无一例侵犯至子宫旁组织(100%),8例为T1期(89%),7例为N0期(78%),7例未见淋巴管癌栓(78%)。EGF-R阳性肿瘤的相应比例范围为52%至67%。然而,仅子宫旁组织侵犯情况存在差异具有统计学意义(EGF-R阴性:0%,EGF-R阳性:38%,p = 0.0306),可能是由于病例数较少。EGF-R表达与肿瘤组织形态学分级无关。本研究结果表明EGF-R表达与肿瘤扩散呈负相关。假设这一趋势能在更大规模患者群体中得到证实,肿瘤活检中EGF-R免疫染色可能有助于为个体患者调整手术策略及辅助治疗。此外,EGF-R是宫颈鳞状细胞癌免疫治疗方法中一个有趣的靶点。